Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction

Edward L. Hannan, Michael Racz, Gary Walford, David Holmes, Robert H. Jones, Samin Sharma, Stanley Katz, Spencer B. King

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objectives: The purpose of this study was to compare outcomes for drug-eluting stents (DES) and bare-metal stents (BMS) for patients with ST-segment elevation myocardial infarction (STEMI). Background: Despite some controversy related to late stent thromboses, DES are approved for use in many patients undergoing stenting. However, there are several types of patients in whom implanting a DES would be regarded as off-label use, and this study compares DES and BMS for one of these groups. Methods: New York's percutaneous coronary intervention registry was used to identify 772 patients undergoing percutaneous coronary intervention (PCI) for STEMI who received BMS and 1,154 STEMI patients who received DES between October 1, 2003, and December 31, 2004. These patients were tracked through December 31, 2005. Mortality, target vessel PCI, and subsequent coronary artery bypass graft (CABG) surgery within 2 years of undergoing the procedure were captured. Adverse outcomes were adjusted using proportional hazards methods to account for baseline differences in patients' severity of illness. Results: The BMS patients had significantly higher mortality (adjusted hazard ratio [HR] vs. DES = 2.01, 95% confidence interval [CI] 1.21 to 3.34, risk-adjusted mortality = 8.6% vs. 5.0%, p = 0.007) and significantly higher subsequent CABG surgery (adjusted HR vs. DES = 2.33, 95% CI 1.31 to 4.16, risk-adjusted rate = 6.4% vs. 3.0%, p = 0.004) rates. There was no difference by type of DES (adjusted HR for paclitaxel-eluting stent versus sirolimus-eluting stent; mortality 0.72, 95% CI 0.30 to 1.72), subsequent CABG surgery (adjusted HR = 0.60, 95% CI 0.26 to 1.40), and target vessel PCI (adjusted HR = 0.74, 95% CI 0.35 to 1.58). Conclusions: In this observational study, DES were associated with lower mortality and subsequent CABG surgery when used for STEMI patients.

Original languageEnglish (US)
Pages (from-to)129-135
Number of pages7
JournalJACC: Cardiovascular Interventions
Volume1
Issue number2
DOIs
StatePublished - Apr 1 2008

Fingerprint

Drug-Eluting Stents
Stents
Metals
Pharmaceutical Preparations
Percutaneous Coronary Intervention
Coronary Artery Bypass
Confidence Intervals
Mortality
Transplants
Therapeutics
Myocardial Infarction
Off-Label Use
ST Elevation Myocardial Infarction
Sirolimus
Paclitaxel
Observational Studies
Registries
Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction. / Hannan, Edward L.; Racz, Michael; Walford, Gary; Holmes, David; Jones, Robert H.; Sharma, Samin; Katz, Stanley; King, Spencer B.

In: JACC: Cardiovascular Interventions, Vol. 1, No. 2, 01.04.2008, p. 129-135.

Research output: Contribution to journalArticle

Hannan, Edward L. ; Racz, Michael ; Walford, Gary ; Holmes, David ; Jones, Robert H. ; Sharma, Samin ; Katz, Stanley ; King, Spencer B. / Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction. In: JACC: Cardiovascular Interventions. 2008 ; Vol. 1, No. 2. pp. 129-135.
@article{4344673384c446c98d70f051c0256328,
title = "Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction",
abstract = "Objectives: The purpose of this study was to compare outcomes for drug-eluting stents (DES) and bare-metal stents (BMS) for patients with ST-segment elevation myocardial infarction (STEMI). Background: Despite some controversy related to late stent thromboses, DES are approved for use in many patients undergoing stenting. However, there are several types of patients in whom implanting a DES would be regarded as off-label use, and this study compares DES and BMS for one of these groups. Methods: New York's percutaneous coronary intervention registry was used to identify 772 patients undergoing percutaneous coronary intervention (PCI) for STEMI who received BMS and 1,154 STEMI patients who received DES between October 1, 2003, and December 31, 2004. These patients were tracked through December 31, 2005. Mortality, target vessel PCI, and subsequent coronary artery bypass graft (CABG) surgery within 2 years of undergoing the procedure were captured. Adverse outcomes were adjusted using proportional hazards methods to account for baseline differences in patients' severity of illness. Results: The BMS patients had significantly higher mortality (adjusted hazard ratio [HR] vs. DES = 2.01, 95{\%} confidence interval [CI] 1.21 to 3.34, risk-adjusted mortality = 8.6{\%} vs. 5.0{\%}, p = 0.007) and significantly higher subsequent CABG surgery (adjusted HR vs. DES = 2.33, 95{\%} CI 1.31 to 4.16, risk-adjusted rate = 6.4{\%} vs. 3.0{\%}, p = 0.004) rates. There was no difference by type of DES (adjusted HR for paclitaxel-eluting stent versus sirolimus-eluting stent; mortality 0.72, 95{\%} CI 0.30 to 1.72), subsequent CABG surgery (adjusted HR = 0.60, 95{\%} CI 0.26 to 1.40), and target vessel PCI (adjusted HR = 0.74, 95{\%} CI 0.35 to 1.58). Conclusions: In this observational study, DES were associated with lower mortality and subsequent CABG surgery when used for STEMI patients.",
author = "Hannan, {Edward L.} and Michael Racz and Gary Walford and David Holmes and Jones, {Robert H.} and Samin Sharma and Stanley Katz and King, {Spencer B.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.jcin.2008.01.006",
language = "English (US)",
volume = "1",
pages = "129--135",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction

AU - Hannan, Edward L.

AU - Racz, Michael

AU - Walford, Gary

AU - Holmes, David

AU - Jones, Robert H.

AU - Sharma, Samin

AU - Katz, Stanley

AU - King, Spencer B.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Objectives: The purpose of this study was to compare outcomes for drug-eluting stents (DES) and bare-metal stents (BMS) for patients with ST-segment elevation myocardial infarction (STEMI). Background: Despite some controversy related to late stent thromboses, DES are approved for use in many patients undergoing stenting. However, there are several types of patients in whom implanting a DES would be regarded as off-label use, and this study compares DES and BMS for one of these groups. Methods: New York's percutaneous coronary intervention registry was used to identify 772 patients undergoing percutaneous coronary intervention (PCI) for STEMI who received BMS and 1,154 STEMI patients who received DES between October 1, 2003, and December 31, 2004. These patients were tracked through December 31, 2005. Mortality, target vessel PCI, and subsequent coronary artery bypass graft (CABG) surgery within 2 years of undergoing the procedure were captured. Adverse outcomes were adjusted using proportional hazards methods to account for baseline differences in patients' severity of illness. Results: The BMS patients had significantly higher mortality (adjusted hazard ratio [HR] vs. DES = 2.01, 95% confidence interval [CI] 1.21 to 3.34, risk-adjusted mortality = 8.6% vs. 5.0%, p = 0.007) and significantly higher subsequent CABG surgery (adjusted HR vs. DES = 2.33, 95% CI 1.31 to 4.16, risk-adjusted rate = 6.4% vs. 3.0%, p = 0.004) rates. There was no difference by type of DES (adjusted HR for paclitaxel-eluting stent versus sirolimus-eluting stent; mortality 0.72, 95% CI 0.30 to 1.72), subsequent CABG surgery (adjusted HR = 0.60, 95% CI 0.26 to 1.40), and target vessel PCI (adjusted HR = 0.74, 95% CI 0.35 to 1.58). Conclusions: In this observational study, DES were associated with lower mortality and subsequent CABG surgery when used for STEMI patients.

AB - Objectives: The purpose of this study was to compare outcomes for drug-eluting stents (DES) and bare-metal stents (BMS) for patients with ST-segment elevation myocardial infarction (STEMI). Background: Despite some controversy related to late stent thromboses, DES are approved for use in many patients undergoing stenting. However, there are several types of patients in whom implanting a DES would be regarded as off-label use, and this study compares DES and BMS for one of these groups. Methods: New York's percutaneous coronary intervention registry was used to identify 772 patients undergoing percutaneous coronary intervention (PCI) for STEMI who received BMS and 1,154 STEMI patients who received DES between October 1, 2003, and December 31, 2004. These patients were tracked through December 31, 2005. Mortality, target vessel PCI, and subsequent coronary artery bypass graft (CABG) surgery within 2 years of undergoing the procedure were captured. Adverse outcomes were adjusted using proportional hazards methods to account for baseline differences in patients' severity of illness. Results: The BMS patients had significantly higher mortality (adjusted hazard ratio [HR] vs. DES = 2.01, 95% confidence interval [CI] 1.21 to 3.34, risk-adjusted mortality = 8.6% vs. 5.0%, p = 0.007) and significantly higher subsequent CABG surgery (adjusted HR vs. DES = 2.33, 95% CI 1.31 to 4.16, risk-adjusted rate = 6.4% vs. 3.0%, p = 0.004) rates. There was no difference by type of DES (adjusted HR for paclitaxel-eluting stent versus sirolimus-eluting stent; mortality 0.72, 95% CI 0.30 to 1.72), subsequent CABG surgery (adjusted HR = 0.60, 95% CI 0.26 to 1.40), and target vessel PCI (adjusted HR = 0.74, 95% CI 0.35 to 1.58). Conclusions: In this observational study, DES were associated with lower mortality and subsequent CABG surgery when used for STEMI patients.

UR - http://www.scopus.com/inward/record.url?scp=41949125911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949125911&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2008.01.006

DO - 10.1016/j.jcin.2008.01.006

M3 - Article

C2 - 19463290

AN - SCOPUS:41949125911

VL - 1

SP - 129

EP - 135

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 2

ER -